Litcius/Paper detail

High-dose rifapentine with or without moxifloxacin for shortening treatment of pulmonary tuberculosis: Study protocol for TBTC study 31/ACTG A5349 phase 3 clinical trial

Susan E. Dorman, Payam Nahid, Ekaterina V. Kurbatova, Stefan Goldberg, Lorna Bozeman, William J. Burman, Kwok Chiu Chang, Michael Chen, Mark F. Cotton, Kelly E. Dooley, Melissa Engle, Pei-Jean Feng, Courtney V. Fletcher, Phan Ha, Charles M. Heilig, John L. Johnson, Erica Lessem, Beverly Metchock, José M. Miró, Nguyen Viet Nhung, April C. Pettit, Patrick Phillips, Anthony T. Podany, Anne Purfield, Kathleen Robergeau, Wadzanai Samaneka, Nigel Scott, Erin Sizemore, Andrew Vernon, Marc Weiner, Susan Swindells, Richard E. Chaisson

2020Contemporary Clinical Trials57 citationsDOIOpen Access PDF

Topics & Concepts

RifapentineMedicineMoxifloxacinRegimenRifamycinEthambutolTuberculosisClinical trialInternal medicineRandomized controlled trialSurgeryMycobacterium tuberculosisAntibioticsLatent tuberculosisPathologyBiologyMicrobiologyTuberculosis Research and EpidemiologyPneumonia and Respiratory InfectionsInhalation and Respiratory Drug Delivery
High-dose rifapentine with or without moxifloxacin for shortening treatment of pulmonary tuberculosis: Study protocol for TBTC study 31/ACTG A5349 phase 3 clinical trial | Litcius